4549956C-8D25-4B37-894C-E82D5C7684F0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.09855453350854139
- age_years
- 24
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.516
- G2M_CHECKPOINT+0.387
- MITOTIC_SPINDLE+0.369
- WNT_BETA_CATENIN_SIGNALING+0.369
- TGF_BETA_SIGNALING+0.359
- MYC_TARGETS_V2+0.316
- HEDGEHOG_SIGNALING+0.297
- MYC_TARGETS_V1+0.284
- E2F_TARGETS+0.264
- UV_RESPONSE_DN+0.236
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.401
- INTERFERON_ALPHA_RESPONSE-0.397
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- MYOGENESIS-0.387
- TNFA_SIGNALING_VIA_NFKB-0.352
- INFLAMMATORY_RESPONSE-0.341
- COAGULATION-0.336
- INTERFERON_GAMMA_RESPONSE-0.330
- ALLOGRAFT_REJECTION-0.306
- KRAS_SIGNALING_DN-0.291
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.941 |
| 2 | SRR934805 | — | — | 0.918 |
| 3 | SRR934951 | — | — | 0.917 |
| 4 | E6090BC6-D29D-4401-990A-251930CC6853 | — | — | 0.914 |
| 5 | SRR934847 | — | — | 0.913 |
| 6 | SRR934858 | — | — | 0.913 |
| 7 | SRR934849 | — | — | 0.912 |
| 8 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.905 |
| 9 | 2DA298A9-AB20-4F9D-B83F-C7FC0679F889 | — | — | 0.903 |
| 10 | 0730F3DB-384B-43E6-A69F-BF3F7C2CCE78 | — | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.516 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.387 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.369 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.369 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.359 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.316 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.297 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.284 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.264 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.236 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.185 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.067 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.059 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.024 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.015 | Inavolisib | — uncovered |